On Tuesday, Verona Pharma Plc ADR (NASDAQ: VRNA) was -4.33% drop from the session before settling in for the closing price of $94.58. A 52-week range for VRNA has been $14.15 – $99.01.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 7.21% annually for the last half of the decade. When this article was written, the company’s average yearly earnings per share was at 175.26%. With a float of $76.70 million, this company’s outstanding shares have now reached $85.13 million.
In an organization with 209 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 94.72%, operating margin of -116.27%, and the pretax margin is -131.25%.
Verona Pharma Plc ADR (VRNA) Insider Updates
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Verona Pharma Plc ADR stocks. The insider ownership of Verona Pharma Plc ADR is 9.90%, while institutional ownership is 76.29%. The most recent insider transaction that took place on Jun 16 ’25, was worth 922,000. In this transaction General Counsel of this company sold 80,000 shares at a rate of $11.53, taking the stock ownership to the 359,999 shares. Before that another transaction happened on Jun 11 ’25, when Company’s Chief Financial Officer sold 400,000 for $11.40, making the entire transaction worth $4,560,360. This insider now owns 12,278,992 shares in total.
Verona Pharma Plc ADR (VRNA) Performance Highlights and Predictions
According to the Wall Street analysts, stocks earnings will be around 175.26% per share during the next fiscal year.
Verona Pharma Plc ADR (NASDAQ: VRNA) Trading Performance Indicators
You can see what Verona Pharma Plc ADR (VRNA) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 8.73. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 64.97.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.04, a number that is poised to hit 0.02 in the next quarter and is forecasted to reach 1.18 in one year’s time.
Technical Analysis of Verona Pharma Plc ADR (VRNA)
Let’s dig in a bit further. During the last 5-days, its volume was 1.01 million. That was inferior than the volume of 1.43 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 35.09%.
During the past 100 days, Verona Pharma Plc ADR’s (VRNA) raw stochastic average was set at 83.54%, which indicates a significant increase from 25.24% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 36.10% in the past 14 days, which was lower than the 53.43% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $78.78, while its 200-day Moving Average is $55.27. However, in the short run, Verona Pharma Plc ADR’s stock first resistance to watch stands at $95.35. Second resistance stands at $100.23. The third major resistance level sits at $103.01. If the price goes on to break the first support level at $87.69, it is likely to go to the next support level at $84.91. Assuming the price breaks the second support level, the third support level stands at $80.03.
Verona Pharma Plc ADR (NASDAQ: VRNA) Key Stats
There are 81,080K outstanding shares of the company, which has a market capitalization of 7.70 billion. As of now, sales total 42,280 K while income totals -173,420 K. Its latest quarter income was 76,260 K while its last quarter net income were -16,320 K.
